BETA: Please send your feedback!
Xencor
XNCR:NAS
Biotechnology
$0
SMALL cap
$39.32
(-0.33%)
0.10%
since start of 2019
62.09
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Bruce Leonard Andrews Carter, PhD | Chairman | Male |
| Bassil I. Dahiyat, PhD | President, Chief Executive Officer & Director | Male |
| John J. Kuch, CPA | Secretary & Vice President-Finance | Male |
| John R. Desjarlais, PhD | Chief Scientific Officer & Senior VP-Research | Male |
| Paul A. Foster, MD | Chief Medical Officer & Senior Vice President | Male |
| Stephen L. Mayo, PhD | Founder | Male |
| Mark W. Lotz | Vice President-Regulatory Affairs | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
Xencor - Competitors and Related Companies
How Xencor stacks up to its peers in the Biotechnology industry or with competing business segments.
Xencor
XNCR:NAS
Biotechnology
$0
SMALL cap
$39.32
(-0.33%)
0.10%
since start of 2019
62.09
MacroGenics
MGNX:NAS
Biotechnology
$448.81mm
SMALL cap
$9.18
(-0.15%)
-0.28%
since start of 2019
-2.54
Seattle Genetics
SGEN:NAS
Biotechnology
$19.35bn
MID cap
$112.88
(-1.10%)
0.97%
since start of 2019
-60.42
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
$24.23bn
LARGE cap
$109.49
(-1.71%)
0.12%
since start of 2019
16.66
AbbVie
ABBV:NYS
Pharmaceuticals: Major
$128.49bn
MEGA cap
$86.89
(0.33%)
-0.03%
since start of 2019
39.84
Amgen
AMGN:NAS
Biotechnology
$139.24bn
MEGA cap
$234.33
(0.49%)
0.22%
since start of 2019
17.87